FOR IMMEDIATE RELEASE

HURLEY CONSULTING ASSOCIATES LTD. ANNOUNCES APPOINTMENT OF APRIL HEATHER KNIGHT-TRENT, PHARMD AS EXECUTIVE DIRECTOR, REGULATORY AFFAIRS

Summit, New Jersey (September 2016) – Hurley Consulting Associates Ltd., a leading international drug development consulting company recognized for its high level of regulatory expertise, is pleased to announce the appointment of April Heather Knight-Trent, PharmD, as Executive Director, Regulatory Affairs. Dr. Knight-Trent is responsible for regulatory strategy and implementation of that strategy. She is also responsible for planning and management of various client projects at Hurley Consulting with emphasis on facilitating project execution in conjunction with the project team. She also interacts as a Regulatory Affairs liaison with FDA and other health authorities on behalf of clients.

"Dr. Knight-Trent's regulatory expertise and 15 years' experience in the pharmaceutical industry is a valuable addition to Hurley Consulting's Regulatory Affairs group and strengthens our ability to provide clients with sound regulatory advice," said John C. Talian, PhD, Vice President of Regulatory Affairs.

Dr. Margaret E. Hurley, President and CEO of Hurley Consulting Associates, commented: "Dr. Knight-Trent's broad knowledge in Regulatory Affairs and pharmaceuticals enhances Hurley Consulting's capabilities to provide the highest quality contract research services to our clients, which allows them to meet their marketing objectives and fulfill their regulatory requirements."

Before joining Hurley Consulting, Dr. Knight-Trent was Director, Global Regulatory, Safety and Biometrics, Business Operations, at Bristol-Myers Squibb in Princeton, New Jersey. In this capacity she supported the Vice Presidents of Global Regulatory Strategy for all therapeutic areas on resourcing, budget, group capabilities, continuous improvement projects, and staff meetings. She has also held positions in Regulatory Affairs at Zymogenetics (acquired by Bristol-Myers Squibb) in Seattle, Washington; at Bristol-Myers Squibb in France and in Wallingford, Connecticut; and at Hoffmann-La Roche, Inc., in Nutley, New Jersey.

Dr. Knight-Trent holds both a bachelor's degree in biology and a doctor of pharmacy degree from the University of West Virginia. In 2000 and 2001, she was a Rutgers Industrial Pharmacy Post-Doctoral Fellow with Hoffmann-La Roche, Inc., and FDA CDER's Oncology Division. Dr. Knight-Trent is a registered pharmacist in West Virginia, and she is a member of the West Virginia University School of Pharmacy Leadership Council.

"I am thrilled to be joining Hurley Consulting. I hope that my talents and experience can further the success and excellent quality of work for our clients," said Dr. Knight-Trent.

Based in Summit, NJ, Hurley Consulting Associates Ltd. was founded in 1987. The company specializes in finding solutions for its clients' regulatory and commercial development needs. With unique expertise to prepare global regulatory submission documents and dossiers, Hurley Consulting integrates nonclinical, clinical, and manufacturing and control evaluations, performs data analyses, and develops and implements regulatory strategies. With a proven track record of more than twenty-five years' regulatory experience, Hurley Consulting can serve its clients as U.S. agent and authorized representative to FDA for regulated products for the entire IND through NDA process.

Contact Info: Hurley Consulting Associates Ltd.
25 DeForest Avenue, Summit, NJ 07901
Phone: +1-908-273-8490 (Fax: +1-908-273-2680)
solutions@hurleyconsulting.com www.hurleyconsulting.com